Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-HIV Immune Serum Globulin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Anti-HIV Immune Serum Globulin (Human) | DRUG | - |
Inclusion Criteria Patients must have: * Proof of HIV infection. * Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or \> 3 months of AZT therapy. Exclusion Criteria Co-existing Condition:...
Top 20 of 28 competitors
Anti-HIV Immune Serum Globulin is an investigational therapy being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for safety in patients with HIV.
Anti-HIV Immune Serum Globulin is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT. The drug is currently in Phase 1 clinical development for the treatment of HIV Infections.
Anti-HIV Immune Serum Globulin is in Phase 1 clinical development. It is an investigational drug and has not been approved for commercial use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for HIV Infections.
Anti-HIV Immune Serum Globulin has been studied in one clinical trial, identified as NCT00002036, titled 'Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)'. This Phase 1 trial enrolled 12 participants with HIV Infections in the United States and has been completed.
Anti-HIV Immune Serum Globulin is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for HIV Infections. The completed Phase 1 trial focused on safety, and the drug has not yet progressed to later-stage trials or received regulatory approval.